invIOs stands for innovative immuno-oncology and is a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies. invIOs is a fully owned subsidiary of Apeiron Biologics AG.

We have three projects in early stages. One project is in Phase 1, treating patients with our autologous and transient cell therapy to silence the checkpoint inhibitor Cbl-b and activate the innate and adaptive immune system. Other projects are in pre-clinical (using the same platform involving TILs) and a tumor-specific novel small molecule for immune activation upon oral application.